Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Acrivon Therapeutics director Charles M. Baum received a grant of stock options for 20,275 shares of common stock. The options have an exercise price of $1.52 per share and expire on June 16, 2036. All 20,275 options will vest immediately before Acrivon’s next annual stockholder meeting, contingent on his continuous service.
Acrivon Therapeutics, Inc. held its 2026 annual meeting of stockholders, where shareholders approved an Amended and Restated 2022 Equity Incentive Plan. The plan authorizes up to 8,606,723 shares of common stock for equity awards, including an increase of 3,000,000 shares approved at the meeting, and features an annual automatic share reserve increase of 5% of fully diluted shares through 2032 unless the Board sets a lower amount.
Shareholders also elected Michael Tomsicek and Charles Baum as Class I directors to serve until the 2029 annual meeting, ratified PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, and approved the amended equity plan. A quorum of 31,336,993.43 shares, representing 73.21% of shares entitled to vote as of April 23, 2026, was present or represented by proxy.
Acrivon Therapeutics reported a routine insider equity adjustment involving its President and CEO, Dr. Peter Blume-Jensen, and EVP of Business Operations, Dr. Kristina Masson. The company withheld 13,729 shares of common stock at $1.79 per share to cover mandatory taxes upon the vesting of restricted stock units, a non‑market transaction classified as a tax-withholding disposition. Following this, Dr. Blume-Jensen directly holds 2,245,317 shares of common stock, and the filing also lists 386,343 shares of common stock as indirectly held between the spouses, with each disclaiming beneficial ownership beyond their pecuniary interest.
RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics, Inc. reported a compensation-related equity award involving entities affiliated with RA Capital. Director Derek DiRocco received a grant of 9,366 restricted stock units (RSUs), each representing one share of common stock at a price of $0.00 per share. The RSUs vest in full on March 18, 2027, if he continues serving as a director through that date. Under his arrangement with RA Capital Management, L.P. as investment manager, Dr. DiRocco holds these RSUs for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. and must deliver any settled shares to the adviser to offset advisory fees. As of this filing, 426,302 shares of common stock are held indirectly by the Fund and 11,803,094 shares are held indirectly by Nexus Fund II. The reporting persons and related parties disclaim beneficial ownership of the RSUs and underlying common stock except to the extent of any pecuniary interest.
Acrivon Therapeutics, Inc. director Michael John Tomsicek reported an equity compensation grant. He acquired 9,366 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost. Each RSU represents one share, and the award vests in full on May 18, 2027, subject to his continuous service.
Shacham Sharon reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics director Sharon Shacham received an equity grant in the form of restricted stock units. The award covers 9,366 RSUs, each representing a right to receive one share of Acrivon common stock at no purchase price. These RSUs vest in full on May 18, 2027, provided she remains in continuous service through that date. Following this grant, her reported direct holdings total 9,366 shares.
Palani Santhosh reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics director Palani Santhosh reported an equity grant. He received 9,366 shares of Common Stock in the form of restricted stock units (RSUs), awarded as compensation rather than an open-market purchase. Each RSU represents a right to receive one share of Common Stock.
The RSUs will vest in full on May 18, 2027, if he continues to serve through that date. Following this grant, the filing shows 9,366 shares held directly, reflecting his entire reported position in this filing.
Acrivon Therapeutics, Inc. director Ivana Magovcevic-Liebisch received an equity award in the form of 9,366 restricted stock units of common stock. The award was granted at no cash cost to her and represents a compensation-related acquisition rather than an open-market purchase.
Each restricted stock unit gives her the right to receive one share of Acrivon common stock, but the units will vest in full only on May 18, 2027, provided she continues to serve the company through that date. Following this grant, her reported direct holding from this award is 9,366 shares, highlighting a single, time-based vesting grant rather than ongoing trading activity.
Acrivon Therapeutics director Derek DiRocco received a grant of 9,366 restricted stock units (RSUs) of Common Stock. The award was made as a grant or other acquisition at a price of $0.00 per share, leaving 9,366 shares reported as held after the transaction.
Each RSU represents a contingent right to receive one share of Acrivon Therapeutics, Inc. Common Stock and will vest in full on May 18, 2027, subject to continuous service through that date. Under DiRocco’s arrangement with RA Capital Management, L.P., he holds the RSUs for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., must turn over any stock received upon settlement to RA Capital Management, and therefore disclaims beneficial ownership of these RSUs and the underlying common stock.
BAUM CHARLES M reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics director Charles M. Baum received an equity grant in the form of restricted stock units. The Form 4 reports an award of 9,366 shares of Common Stock at no purchase price, increasing his directly held stake to 9,366 shares.
The footnotes explain these are RSUs, each representing a contingent right to receive one share of Common Stock. The RSUs vest in full on May 18, 2027, provided Baum remains in continuous service with the company through that vesting date.